甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病患儿的长期随访研究

目的探究甲磺酸伊马替尼联合VDLD化疗方案治疗急性淋巴细胞白血病(ALL)患儿的应用价值。方法选取2015年5月~2018年6月收治的74例ALL患儿,按照治疗方案不同分组。对照组(37例)实施VDLD方案治疗,联合组(37例)实施甲磺酸伊马替尼+VDLD化疗方案治疗。对比两组疗效、不良反应发生率、随访1年无复发生存率(RFS)及治疗前、治疗2个疗程后血清B淋巴细胞刺激因子(BAFF)、增殖诱导配体(APRIL)水平。结果联合组总有效率(91.89%)高于对照组(72.97%)(P<0.05);联合组治疗2个疗程后血清BAFF、APRIL水平低于对照组(P<0.05);两组不良反应发生率、随访1年RFS对比无显著差异(P>0.05)。结论甲磺酸伊马替尼联合VDLD化疗方案治疗ALL,疗效确切,能显著降低血清BAFF、APRIL水平,且安全性高。

Long-term follow-up study of imatinib mesylate combined with VDLD chemotherapy in children with acute lymphoblastic leukemia

Objective To investigate the application value of imatinib mesylate combined with VDLD chemotherapy in children with acute lymphoblastic leukemia(ALL).Methods 74 children with ALL in our hospital(May 2015 to June 2018)were selected and grouped according to the treatment plan.The control group(37 cases)was treated with VDLD regimen,and the combined group(37 patients)was treated with imatinib mesylate+VDLD chemotherapy.The efficacy of the two groups,the incidence of adverse reactions,the 1-year recurrence-free survival rate(RFS),and the serum B-lymphocyte stimulating factor(BAFF)and proliferation-inducing ligand(APRIL)levels were measured before and after treatment.Results The total effective rate(91.89%)was higher in the combined group than in the control group(72.97%,P<0.05).The serum BAFF and APRIL levels in the combined group were lower than those in the control group(P<0.05).There was no significant difference in RFS between the rate and follow-up for 1 year(P>0.05).Conclusion Imatinib mesylate combined with VDLD chemotherapy is effective in treating ALL.It can significantly reduce serum BAFF and APRIL levels and has high safety.